Halozyme Therapeutics HALO Free cash flow margin
Free cash flow margin at other companies
Other financials
Where this comes from
Calculated from Halozyme Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's free cash flow margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's free cash flow margin?
- Halozyme Therapeutics (HALO) reported free cash flow margin of 44.3% in Q1 2026.
- How has Halozyme Therapeutics's free cash flow margin changed year-over-year?
- Halozyme Therapeutics's free cash flow margin decreased by 3.2% year-over-year, from 45.7% to 44.3%.
- What is the long-term trend for Halozyme Therapeutics's free cash flow margin?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's free cash flow margin has grown at a 18.5% compound annual growth rate (CAGR), from 19.8% to 46.2%.
- What does free cash flow margin mean?
- How much real, spendable cash each sales dollar generates after reinvestment.
- How do you interpret free cash flow margin?
- A high and rising FCF margin is the hallmark of a cash-generative business. Persistent gaps between net margin and FCF margin warrant a look at working capital or capital intensity.
- How does free cash flow margin compare across companies?
- Strong cross-company quality signal; capital-light compounders post structurally higher FCF margins than asset-heavy peers.